Carlsmed, Inc. (NASDAQ:CARL) Receives Average Rating of "Hold" from Analysts

Key Points

• Analyst consensus: Carlsmed carries an average rating of "Hold" (2 sell, 3 buy) with a mean 12‑month price target of $21.33, implying substantial upside from the current ~$10.40 share price.
• Recent results showed an EPS beat (loss of $0.32 vs. consensus -$0.43) but a slight revenue miss ($15.16M vs. $15.20M); the company remains unprofitable with negative ROE and net margin.
• Shares trade around $10.40 (1‑year range $9.80–$17.19) with a market cap of about $278M; Carlsmed reports strong liquidity (current ratio 8.87) low leverage (debt/equity 0.16), and several institutional investors recently initiated positions.

Carlsmed, Inc. (NASDAQ:CARL - Get Free Report) has been given an average rating of "Hold" by the five ratings firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $21.3333.

CARL has been the topic of a number of recent analyst reports. Weiss Ratings restated a "sell (e-)" rating on shares of Carlsmed in a research report on Monday, December 22nd. Zacks Research downgraded shares of Carlsmed from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 25th. Wall Street Zen upgraded shares of Carlsmed from a "sell" rating to a "hold" rating in a report on Saturday, February 14th. The Goldman Sachs Group reiterated a "buy" rating and set a $20.00 price target on shares of Carlsmed in a report on Friday, January 9th. Finally, BTIG Research reissued a "buy" rating and issued a $24.00 price objective on shares of Carlsmed in a research report on Monday, December 15th.

Carlsmed Trading Up 4.1%

Shares of CARL stock opened at $10.40 on Tuesday. Carlsmed has a 1-year low of $9.80 and a 1-year high of $17.19. The company has a current ratio of 8.87, a quick ratio of 8.74 and a debt-to-equity ratio of 0.16. The stock has a market cap of $277.99 million and a price-to-earnings ratio of -2.84. The stock has a 50-day moving average of $12.27 and a 200-day moving average of $13.03.

Carlsmed (NASDAQ:CARL - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.11. The business had revenue of $15.16 million for the quarter, compared to analysts' expectations of $15.20 million. Carlsmed had a negative return on equity of 72.60% and a negative net margin of 58.67%.

Hedge Funds Weigh In On Carlsmed

Institutional investors and hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas acquired a new stake in shares of Carlsmed during the 3rd quarter worth approximately $2,343,000. Kornitzer Capital Management Inc. KS bought a new position in Carlsmed during the third quarter worth $736,000. TD Waterhouse Canada Inc. bought a new position in Carlsmed during the third quarter worth $2,026,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in Carlsmed in the third quarter worth $335,000. Finally, Rhumbline Advisers bought a new stake in Carlsmed in the third quarter valued at $79,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.